



**INLAND EMPIRE HEALTH PLAN**

September 20, 2010

Dear IEHP Provider,

We would like to inform you of the following changes to the 2010/2011 IEHP Formulary that were approved by the Pharmacy and Therapeutics Subcommittee in August 2010:

<b>Formulary Addition</b>			
<b>Drug Name</b>	<b>Classification</b>	<b>Medi-Cal/HF/HK</b>	<b>DualChoice Formulary</b>
Abreva (docosanol)	Dermatological	Formulary	OTC exclusion- covered through IEHP Medi-Cal benefit
Jalyn (dutasteride and tamsulosin)	BPH Agent	Non-Formulary	Formulary

<b>Formulary Criteria Modification</b>			
<b>Drug Name</b>	<b>Classification</b>	<b>Medi-Cal/HF/HK</b>	<b>DualChoice</b>
Test Strips	DME	Insulin dependent: - 100/30 ds Non-insulin dependent: - 100/90 ds	Insulin dependent: - 100/30 ds Non-insulin dependent: - 100/90 ds

**IMPORTANT INFORMATION ABOUT IEHP CLINICAL PRACTICE GUIDELINES**

IEHP publishes and distributes an IEHP Formulary Book to our Providers every year. The IEHP Formulary Book contains IEHP treatment guidelines for drug therapy of various medical conditions and policies regarding the use of specific drugs. These recommendations (listed below), which have been approved by the Pharmacy and Therapeutics Subcommittee and Quality Management Committee, are based on published consensus guidelines and reviews of the medical literatures, they do not favor any particular drug based solely on cost considerations. All guidelines for therapy are current as of the time of printing and are subject to change. The Clinical Practice Guidelines are reviewed at least once every two years, or when a new update is available prior to the two-year schedule. When a new Clinical

303 E. Vanderbilt Way, Suite 400, San Bernardino, CA 92408  
Tel (909) 890-2049 Fax (909) 890-2058  
Visit our web site at: [www.iehp.org](http://www.iehp.org)

*A Public Entity*

Practice Guideline is available, IEHP communicates the changes to the Provider via this quarterly Formulary Change notice. The guidelines are general and may not cover all clinical situations; they should not be considered in any way as a substitute for sound clinical judgment.

IEHP Clinical Practice Guidelines currently available:

- Attention Deficit Hyperactivity Disorder Guideline and Toolkit
- Anti-Infective Therapy Guide Adult and Pediatric
- Asthma
- Botox
- Depression
- Diabetes Mellitus
- Diabetes Pregnancy
- Fibromyalgia
- Gastroesophageal Reflux Disease
- Hepatitis C
- Hyperlipidemia
- Hypertension
- Migraine
- Multiple Sclerosis
- Pulmonary Arterial Hypertension
- Pain Management
- Rheumatoid Arthritis
- Sexually Transmitted Diseases - Summary of CDC Treatment Guidelines
- Smoking Cessation
- Synagis Criteria Season

We welcome any recommendations and comments regarding the IEHP Formulary. For questions, suggestions, or if you would like a printed copy of the IEHP Formulary Book or Clinical Practice Guideline, please call us at (909) 890-2067. As a reminder, updated formulary information and Clinical Practice Guidelines are available at [www.iehp.org](http://www.iehp.org).

Sincerely,



Chris Chan, Pharm.D.  
Director of Pharmaceutical Services